NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual MeetingOct 4, 2021
NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLCApr 13, 2021
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid TumorsMar 31, 2021